BMYJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanySigning up patients
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 230 (planned)
- Started
- Mar 21, 2024
- Main results expected
- Jul 31, 2026
- Fully finished
- Jun 30, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1: Best overall response (BOR) of partial response (PR) or better
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06297226 · record last updated 2026-10-06 · checked 2026-11-09 15:47 UTC